APRIL 30, 2021
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
Biophytis – Convening of Another Combined General Meeting at a Later Date
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French)
Biophytis Identifies False Report Regarding COVA Study
Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma.
Biophytis gives updates on its Phase 2-3 COVA study on COVID-19
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd
Biophytis AGM meeting will take place on April 26, 2021